Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Frankfurt - Delayed Quote EUR

Roche Holding AG (RHO6.F)

Compare
36.40
0.00
(0.00%)
As of April 3 at 9:41:17 AM GMT+2. Market Open.
Loading Chart for RHO6.F
  • Previous Close 36.40
  • Open 36.40
  • Bid 35.80 x 20000
  • Ask 36.40 x 20000
  • Day's Range 36.40 - 36.40
  • 52 Week Range 27.10 - 40.31
  • Volume 412
  • Avg. Volume 175
  • Market Cap (intraday) 233.481B
  • Beta (5Y Monthly) 0.22
  • PE Ratio (TTM) 26.96
  • EPS (TTM) 1.35
  • Earnings Date Jan 30, 2025
  • Forward Dividend & Yield 1.26 (3.47%)
  • Ex-Dividend Date Mar 28, 2025
  • 1y Target Est --

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.

www.roche.com

103,249

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RHO6.F

View More

Performance Overview: RHO6.F

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

RHO6.F
13.11%
MSCI WORLD (^990100-USD-STRD)
5.65%

1-Year Return

RHO6.F
31.30%
MSCI WORLD (^990100-USD-STRD)
2.91%

3-Year Return

RHO6.F
8.86%
MSCI WORLD (^990100-USD-STRD)
0.00%

5-Year Return

RHO6.F
13.75%
MSCI WORLD (^990100-USD-STRD)
97.47%

Compare To: RHO6.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RHO6.F

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    233.48B

  • Enterprise Value

    253.39B

  • Trailing P/E

    27.01

  • Forward P/E

    13.50

  • PEG Ratio (5yr expected)

    0.68

  • Price/Sales (ttm)

    3.58

  • Price/Book (mrq)

    6.97

  • Enterprise Value/Revenue

    3.88

  • Enterprise Value/EBITDA

    14.58

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.27%

  • Return on Assets (ttm)

    12.75%

  • Return on Equity (ttm)

    26.47%

  • Revenue (ttm)

    62.39B

  • Net Income Avi to Common (ttm)

    8.28B

  • Diluted EPS (ttm)

    1.35

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    17.33B

  • Total Debt/Equity (mrq)

    100.60%

  • Levered Free Cash Flow (ttm)

    13.67B

Research Analysis: RHO6.F

View More

Company Insights: RHO6.F

Research Reports: RHO6.F

View More

People Also Watch